Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96LD4

UPID:
TRI47_HUMAN

ALTERNATIVE NAMES:
Gene overexpressed in astrocytoma protein; RING finger protein 100; Tripartite motif-containing protein 47

ALTERNATIVE UPACC:
Q96LD4; Q96AD0; Q96GU5; Q9BRN7

BACKGROUND:
The protein E3 ubiquitin-protein ligase TRIM47, identified by its alternative names such as Gene overexpressed in astrocytoma protein, RING finger protein 100, and Tripartite motif-containing protein 47, mediates critical cellular mechanisms by targeting CYLD for ubiquitination and subsequent degradation. This activity is essential for the regulation of various cellular processes, including signal transduction and immune responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of E3 ubiquitin-protein ligase TRIM47 offers a promising avenue for the development of novel therapeutic interventions. Given its central role in the ubiquitination pathway, targeting TRIM47 could provide a strategic approach to manipulate this pathway for therapeutic advantage.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.